- The Company will also present updated data at three Congresses - PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 29, 2020 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP),.
If you own shares in Adaptimmune Therapeutics plc (NASDAQ:ADAP) then it's worth thinking about how it contributes to...
ADAP earnings call for the period ending March 31, 2020.
Current Affairs for IAS Exams - 07 May 2020 ::NATIONAL:: Around 40cr people receive financial assistance under various schemes
Adaptimmune Therapeutics plc (“Adaptimmune”) (ADAP), a leader in T-cell therapy to treat cancer, today announced that the underwriters of its previously announced public offering of 21,000,000 American Depositary Shares (“ADSs”), which initially closed on January 24, 2020, have exercised in full their option to purchase an additional 3,150,000 of its ADSs at a price to the public of $4.00 per ADS, raising additional net proceeds of approximately $11.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. After giving effect to the option exercise, Adaptimmune sold a total of 24,150,000 ADSs in connection with the offering, generating net proceeds of approximately $89.8 million, after deducting the underwriting discount and other offering expenses payable by Adaptimmune.
Adaptimmune Therapeutics plc (ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for Orphan Drug Designation for ADP-A2M4 for the treatment of soft tissue sarcomas. Adaptimmune’s SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) is actively enrolling at approximately 25 clinical sites in Canada, France, Spain, the United Kingdom, and the US. The SPEARHEAD-1 trial is intended to support the registration of ADP‑A2M4 for the treatment of advanced synovial sarcoma and MRCLS.
- Upfront payment of $50m received from Astellas and approximately $90m offering completed - - Financial guidance confirmed: funded into 2H 2021 - - Orphan Drug.
Is (ADAP) Outperforming Other Medical Stocks This Year?
It’s kind hard to believe that we started this series just 10 weeks ago, in the before times. This coronavirus pandemic has changed everything. The original goal was a poll-free, spin-free, prognostication-free political thread, and the hope was that this wo…
The final numbers are in: Passage Bio has raised a total of $248.4 million through its initial public offering, setting a new record for an IPO by a Philadelphia-area cell or gene therapy company. Passage Bio initially sold 12 million shares of its stock at $18 per share on Feb. 28, bringing in $216 million in the early days of what has been a volatile three-week run on Wall Street. The gene therapy company spun out of the University of Pennsylvania announced this week the underwriters for the offering exercised their full option to purchase an additional 1.8 million shares, raising the total value of the IPO to $248.4 million.
If you own shares in Adaptimmune Therapeutics plc (NASDAQ:ADAP) then it's worth thinking about how it contributes to...
Author summary Pathogenic Yersinia species carry a virulence plasmid encoding a type 3 secretion system that translocates 6–7 effector Yops into host cells. We demonstrate that YopH protects Yersinia pseudotuberculosis from neutrophil-produced reactive oxygen…
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 18, 2020 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announces.
Cabaletta Bio is pioneering the use of CAAR-T cell therapies to potentially cure various autoimmune diseases.Autoimmunity is a large market, at least $100B, but only having standard-of-care medicines like steroids that lead to nasty side effects and Humira.Th…
Image source: The Motley Fool. Adaptimmune Therapeutics PLC (NASDAQ: ADAP)Q1 2020 Earnings CallMay 14, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorLadies and gentlemen, thank you for standing by, and welcome to the Adaptimmune Q1 2020 Earnings Conference Call.
Q1 2020 Adaptimmune Therapeutics PLC Earnings Call
It’s kind hard to believe that we started this series just 10 weeks ago, in the before times. This coronavirus pandemic has changed everything. The original goal was a poll-free, spin-free, prognostication-free political thread, and the hope was that this wo…
- Compelling data in synovial sarcoma in the Phase 1 trial, and continued momentum in the Phase 2 SPEARHEAD-1 trial with goal to launch ADP‑A2M4 for sarcoma in 2022 -.
NADA hearings have not been taking place due to the lockdown to contain the COVID-19 pandemic.
PHILADELPHIA and OXFORDSHIRE, United Kingdom, Feb. 20, 2020 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial.
Cabaletta Bio is pioneering the use of CAAR-T cell therapies to potentially cure various autoimmune diseases.Autoimmunity is a large market, at least $100B, but only having standard-of-care medicines like steroids that lead to nasty side effects and Humira.Th…
Q4 2019 Adaptimmune Therapeutics PLC Earnings Call
Focused on using engineering cells to help the immune system recognize and fight cancer, the company made waves when it showed activity against solid tumors. The engineered T cells increase the immune system's ability to detect cancer cells and destroy them. This method of tweaking patients' own cells and then giving the cells back to them has led to two Food and Drug Administration (FDA) approved cell therapies: Yescarta from Gilead and Kymriah from Novartis.
Navin Agarwal said athletes will be allowed to participate via audio calls to ensure that things can be managed smoothly, in case of internet connectivity issues
“What are we going to do? How are we going to test everybody?”
- Edited stem-cell derived T-cells can kill MAGE-A4+ cancer targets in vitro - - T-cell receptor expression edited in to stem cells - a milestone to build cell banks for.
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.Large-cap pharma names AstraZeneca plc (NYSE: AZN) a…
NEW YORK, NY / ACCESSWIRE / February 27, 2020 / Adaptimmune Therapeutics Plc (NASDAQ:ADAP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on February 27, ...
The Pleasanton Downtown Association has been encouraging residents to take a turn playing
Adaptimmune Therapeutics PLC (ADAP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Adaptimmune Therapeutics plc (NASDAQ:ADAP) just released its latest yearly report and things are not looking great. It...
NEW YORK, May 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, UPWK, ERI, CODX, and DAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selec…
As Jaguar announced this past Wednesday, May 13, 2020, Mytesi sales in April 2020 to Cardinal Health have a gross value of $2,753,639. As with all Mytesi gross sales, this figure will be reduced by Medicare, ADAP 340B chargebacks, returns, and wholesale distr…
The company's new CEO has a new leadership team in place and money in the bank as its works to advance its cell therapies for solid tumors.
Shares of Adaptimmune Therapeutics (NASDAQ:ADAP) rose 1.3% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were flat 0.00% year over year to ($0.04), which beat the estimate of ($0.25).Revenue of $761,000 rose by 0.00% from the same period last year, which missed the estimate of $23,290,000.Outlook Adaptimmune Therapeutics hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 14, 2020View more earnings on ADAPTime: 08:02 PM ETWebcast URL: https://edge.media-server.com/mmc/p/4772jrtcTechnicals 52-week high: $6.0052-week low: $0.71Price action over last quarter: Up 27.07%Company Description Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.See more from Benzinga * Meredith: Q3 Earnings Insights * Wabash National: Q1 Earnings Insights * Recap: Aemetis Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.